The cumulative risk of endometrial cancer in EPCAM deletion carriers is lower than that in MSH2 variant carriers, while the cumulative risk of colorectal cancer in EPCAM deletion carriers is similar to that in MSH2 variant carriers10. Here, MSH2 is linked to endometrial cancer.